Meeting
2018 ASCO Annual Meeting
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
Authors
Patrick McKay Boland
Roswell Park Cancer Institute, Buffalo, NY
Patrick McKay Boland , Marwan Fakih , Dean Lim , Kristopher Attwood , Wei Tan , Michalis Mastri , Robert Bies , Christos Fountzilas , Renuka V. Iyer , Wen Wee Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02393755
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3552)
DOI
10.1200/JCO.2018.36.15_suppl.3552
Abstract #
3552
Poster Bd #
45
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
First Author: Patrick McKay Boland
Poster
2016 ASCO Annual Meeting
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
First Author: Yasutoshi Kuboki
Poster
2022 ASCO Annual Meeting
Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.
First Author: Antoine Adenis
Poster
2015 ASCO Annual Meeting
An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE).
First Author: Yasutoshi Kuboki